News
Patheon Announces Official Opening Of Milton Park Early Phase Development Center In Oxfordshire, UK
April 14, 2008
Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, recently announced that it has officially opened a new early phase development facility located in Milton Park in Oxfordshire, UK.
The 13,500 square foot (1,250 square meter) leased development facility contains newly constructed formulation laboratories and a fully equipped analytical laboratory. Milton Park Operations will focus on the early phase development of solid, semi-solid and oral liquid dosage forms. The facility includes GMP manufacturing areas for the production of clinical trial materials for Phase I/II trials. Patheon's Quick To Clinic programs, which accelerate molecules to clinical trials while minimizing API requirements, will be supported at the site. The new development facility holds an Investigational Medical Product License from the MHRA (UK) and is already working on a number of development projects.
"The Milton Park facility was created to meet our customers' growing demand for rapid early phase development capacity in a strategic location", said Norman Barras Vice-President, Pharmaceutical Development Services, Europe. "We believe that our Quick to Clinic approach will provide a valuable opportunity to shorten the development times of our customers' projects."
"Milton Park is one of many significant additions that we plan to make in our development service offerings", added Wes Wheeler, Chief Executive Officer. "We are constantly striving to understand our customers' needs and then respond accordingly."
About Patheon
Patheon is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 10 manufacturing and six development facilities in the United States, Canada and Europe, employing more than 4,700 people and serving a customer base of 270 pharmaceutical and biotechnology companies.
SOURCE: Patheon Inc.
